OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up

(RTTNews) - OS Therapies, Inc. (OSTX) Wednesday announced that it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals (ADXS).

Under the agreement, OS Therapies will pay $0.5 million in cash and issue $7.5 million in common shares to Ayala.

This acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, as well as full ownership of the IP related to OS Therapies' lead asset, OST-HER2, for osteosarcoma and other HER2-related indications.

The transaction is expected to close within 60 days from execution of the deal.

Meanwhile, OS Therapies anticipates requesting Biologics Licensing Authorization for OST-HER2 in osteosarcoma in the second quarter of 2025 and expects to be granted a BLA and related Priority Review Voucher from FDA by the end of 2025.

Previously, OS Therapies stated that it has secured $7.1 million in funding at $4.00 per share, ensuring financial stability through 2026, including payments to Ayala.

OSTX is currently trading at $2.85 up 9.61 percent or $0.25 on the New York Stock Exchange.